Renata Valuation

Q: What is the Fair Price of RENATA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

RENATA (BDT661.6) is trading above our estimate of [[fair value]] (BDT541.88)

Is RENATA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RENATA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RENATA (BDT661.6) is trading above our estimate of fair value (BDT541.88)

Significantly Below Fair Value: RENATA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RENATA?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for RENATA. This is calculated by dividing RENATA's market cap by their current preferred multiple.
What is RENATA's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	৳75.88b

RENATA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.5x
Enterprise Value/EBITDA	20.9x
PEG Ratio	1.1x

Price to Earnings Ratio vs Peers

How does RENATA's PE Ratio compare to its peers?

The above table shows the PE ratio for RENATA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20.6x
BXPHARMA Beximco Pharmaceuticals	6.2x	15.6%	৳33.1b
SQURPHARMA Square Pharmaceuticals	9.6x	12.6%	৳194.8b
BEACONPHAR Beacon Pharmaceuticals	59.8x	n/a	৳27.9b
ACMELAB ACME Laboratories	6.9x	n/a	৳16.8b
RENATA Renata	33.1x	29.0%	৳75.9b

Price-To-Earnings vs Peers: RENATA is expensive based on its Price-To-Earnings Ratio (33.1x) compared to the peer average (20.6x).

Price to Earnings Ratio vs Industry

How does RENATA's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.1%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: RENATA is expensive based on its Price-To-Earnings Ratio (33.1x) compared to the Asian Pharmaceuticals industry average (25.1x).

Price to Earnings Ratio vs Fair Ratio

What is RENATA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RENATA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	33.1x
Fair PE Ratio	15.9x

Price-To-Earnings vs Fair Ratio: RENATA is expensive based on its Price-To-Earnings Ratio (33.1x) compared to the estimated Fair Price-To-Earnings Ratio (15.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.